ライフサイエンスコーパス: LAM

1 LAM causes cystic remodeling of the lung and progressive

2 LAM cell selective markers, secreted biomarkers, and the

3 LAM cells in lung and uterus are morphologically indisti

4 LAM ELISA had the following sensitivity, specificity, po

5 LAM is an elegant model of malignancy because biallelic

6 LAM is characterized by neoplastic growth of smooth musc

7 LAM LFA had a sensitivity of 50% for definite and probab

8 LAM LFA had a sensitivity of 68% for the composite stand

9 LAM LFA had a sensitivity of 75% for definite histopatho

10 LAM LFA in CSF is a useful additional diagnostic tool.

11 LAM(CORE) cells expressing signature genes included know

12 LAM-HTGTS assays are sensitive, reproducible, relatively

13 LAM-HTGTS differs from related approaches because it det

14 Xpert tests improved case finding by 21.6%, LAM testing alone improved it by 13.5%, and dual Xpert t

15 care, and who would thus be ineligible for a LAM test under current guidelines.

16 s or an intact Golgi, but depends on Ltc1, a LAM/StARkin-family protein localized to ER-PM contact si

17 Here, we profile a LAM lung compared to an age- and sex-matched healthy con

18 down of GRAIL before LAM treatment abrogated LAM-induced hyporesponsiveness.

19 s and develop therapeutic strategies against LAM.

20 ulture as a reference standard (Xpert alone, LAM alone, sequential Xpert followed by LAM and vice ver

21 Lysine 2,3-aminomutase (LAM) is a radical S-adenosyl-L-methionine (SAM) enzyme a

22 001), while Beijing (OR, 0.6; P = 0.006) and LAM (OR, 0.7; P = 0.07) strains clustered less.

23 acilli without significantly altering AG and LAM biosynthesis.

24 in Mycobacterium smegmatis abolished AG and LAM succinylation and altered the hydrophobicity and rig

25 to an important role of SucT-mediated AG and LAM succinylation in modulating the cell surface propert

26 AML and LAM are etiologically linked to mutations in the tsc2 an

27 logically slowing the progression of AML and LAM with rapamycin, our understanding of their pathogene

28 CNS involvement, renal and hepatic AMLs and LAM, even if clinical signs are not obvious.

29 GIT) and Lowenstein-Jensen (LJ) culture, and LAM-ELISA.

30 required for synthesis of full-length LM and LAM.

31 e with alpha-mannosidase (for human TB), and LAM-spiked milk with combined lactase and caseinase (for

32 We propose that a subset of cells in TSC and LAM lesions have additional signaling aberrations, thus

33 tment is proposed for the control of TSC and LAM lesions, which increases the chances for the develop

34 ential therapeutic opportunities for TSC and LAM.

35 palogs) are approved for treating of TSC and LAM.

36 th both tuberous sclerosis complex (TSC) and LAM (TSC-LAM) into induced pluripotent stem cells (iPSC)

37 oth tests, concurrent testing with Xpert and LAM may be the best strategy for diagnosing TB.

38 owever, how to optimally integrate Xpert and LAM tests into clinical practice algorithms remain uncle

39 lere Determine TB lipoarabinomannan antigen (LAM-test) is a World Health Organization-endorsed point-

40 sandwich enzyme-linked immunosorbent assay (LAM-ELISA) was developed to quantitate LAM concentration

41 us conclusions and suggest Norse activity at LAM may have endured for a century.

42 In August 2018, we undertook fieldwork at LAM to sample the peat bog 30 m east of the Norse ruins

43 n used along with rapamycin, might attenuate LAM progression and potentially other TSC-related disord

44 ering RNA-mediated knockdown of GRAIL before LAM treatment abrogated LAM-induced hyporesponsiveness.

45 Among both LAM and MGIT MTB-culture-positive samples, log10-transfo

46 ibition of human CD4(+) T cell activation by LAM also was associated with increased GRAIL expression.

47 Induction of CD4(+) T cell anergy by LAM may represent one mechanism by which M. tuberculosis

48 wth factors and matrix remodeling enzymes by LAM cells enables their access to lymphatic channels and

49 one, LAM alone, sequential Xpert followed by LAM and vice versa [LAM in Xpert-negative patients and X

50 zation of L-alpha-lysine to L-beta-lysine by LAM, via the stable allylic anhydroadenosyl radical (anA

51 ign-appearing spindle and epithelioid cells (LAM cells) that express smooth-muscle and melanocyte-lin

52 Combining LAM with AFB had an AUROC = 0.68 (95% CI 0.59-0.77), sig

53 ) detects Mycobacterium tuberculosis complex LAM in urine, and its use is recommended for TB diagnosi

54 tive patients], and both tests concurrently [LAM + Xpert]).

55 sts were CSF Xpert MTB/RIF, 52.9%/94.2%; CSF LAM, 21.9%/94.2%; urine LAM, 24.1%/76.1%; and CSF glucos

56 CSF Xpert MTB/RIF and CSF LAM are highly specific for the diagnosis of TBM.

57 A model including CSF Xpert MTB/RIF, CSF LAM, CSF glucose, and CSF total protein demonstrated an

58 ts indicate that the LAM-ELISA can determine LAM concentration in sputum, and sputum LAM measured by

59 b1, CS35, and A194, which recognize distinct LAM epitopes, a one-sided immunoassay, and blinded cohor

60 e for diagnosing TB in PLHIV than an earlier LAM assay (Alere Determine TB LAM lateral flow assay [LF

61 The arabinosyltransferase EmbC required for LAM biosynthesis is essential.

62 acidification may be potential therapies for LAM.

63 However, deploying a future LAM test for all people presenting to care with TB sympt

64 idemiological impact that current and future LAM tests may have on TB incidence and mortality.

65 ative to this comparator, current and future LAM tests would respectively avert 54 (95% CrI 33-86) an

66 ulated the hypothetical deployment of future LAM tests for all people presenting to care with TB symp

67 igh-HIV-burden settings, will require future LAM tests to have sufficient performance to be deployed

68 mutations was a viable approach to generate LAM-like cells.

69 In LAM cell-fibroblast co-cultures, acidification parallele

70 otein and protease activity were detected in LAM-associated fibroblasts but not the LAM cell line 621

71 biogenesis and mitochondrial dysfunction in LAM cells provide a novel target for treatment.

72 nfirmed cathepsin K protein was expressed in LAM but not control lungs.

73 nic anhydrases, which were also expressed in LAM lung tissue.

74 ection of cells that resemble those found in LAM tumors by unbiased in vivo differentiation.

75 nd define molecular and cellular networks in LAM.Measurements and Main Results: A unique cell type te

76 gene expression was 40-fold overexpressed in LAM compared with control lung tissue (P </= 0.0001).

77 rmful side reactions: this "free radical" in LAM is never free.

78 nal antibodies binding to epitopes unique in LAM from MTB and slow-growing nontuberculous mycobacteri

79 [LAM in Xpert-negative patients and Xpert in LAM-negative patients], and both tests concurrently [LAM

80 ls expressing signature genes included known LAM markers such as PMEL, FIGF, CTSK, and MLANA and nove

81 Laminarin (LAM-OH) is a highly abundant, nontoxic, degradable polys

82 itis B patients with preexisting lamivudine (LAM) resistance (LAM-R) undergoing liver transplantation

83 LF-LAM was positive in 19 of 21 patients without evidence o

84 sed LAM test, Alere Determine TB LAM Ag ('LF-LAM'), performs best in the sickest people living with H

85 nded double reading, with SILVAMP-LAM and LF-LAM.

86 the Determine TB-LAM lateral flow assay (LF-LAM) results among human immunodeficiency virus-infected

87 lere Determine TB LAM lateral flow assay [LF-LAM]).

88 ompared to 25.3% (95% CI 15.8%-34.9%) for LF-LAM.

89 compared to 10.9% (95% CI 5.2%-18.4%) for LF-LAM.

90 ompared to 56.0% (95% CI 43.9%-64.9%) for LF-LAM.

91 ompared to 34.9% (95% CI 19.5%-50.9%) for LF-LAM.

92 s 65.8% (95% CI 55.9%-74.6%), and that of LF-LAM 31.4% (95% CI 19.1%-43.7%).

93 s 90.9% (95% CI 87.2%-93.7%), and that of LF-LAM 95.3% (95% CI 92.2%-97.7%).

94 ated NTM disease may cause false-positive LF-LAM results.

95 r proportion of TB patients in PLHIV than LF-LAM.

96 ' tests (with sensitivity consistent with LF-LAM), from hypothetical 'future' tests (having sensitivi

97 rabinomannan (LAM) lateral flow assay (LFA), LAM enzyme-linked immunosorbent assay (ELISA), and Xpert

98 The currently licensed LAM test, Alere Determine TB LAM Ag ('LF-LAM'), performs

99 lastic growth of atypical smooth muscle-like LAM cells in the pulmonary interstitial space that leads

100 Lipoarabinomannan (LAM) is a major antigen of Mycobacterium tuberculosis (M

101 Lipoarabinomannan (LAM), a surface glycolipid, has been identified as a pot

102 arabinogalactan (AG) and lipoarabinomannan (LAM).

103 ed whether mannose-capped lipoarabinomannan (LAM)-induced inhibition of CD4(+) T cell activation resu

104 (CSF) Xpert MTB/RIF, CSF lipoarabinomannan (LAM), urine LAM, CSF total protein, and CSF glucose comp

105 osis-specific glycolipid, lipoarabinomannan (LAM), a promising urinary biomarker for the detection an

106 ct the lipopolysaccharide lipoarabinomannan (LAM), present in mycobacterial cell walls, can provide r

107 nd pericardial fluid (PF) lipoarabinomannan (LAM) assays in tuberculous pericarditis (TBP).

108 mmunogenic polysaccharide lipoarabinomannan (LAM).

109 etects the presence of TB lipoarabinomannan (LAM) in urine, and is substantially more sensitive for d

110 iagnostic accuracy of the lipoarabinomannan (LAM) lateral flow assay (LFA), LAM enzyme-linked immunos

111 orbent assay, and urinary lipoarabinomannan (LAM) by Alere Determine TB LAM assay.

112 Both a urinary lipoarabinomannan (LAM) test (Alere TB LAM) and GeneXpert-MTB/RIF (Xpert) a

113 Lateral flow urine lipoarabinomannan (LAM) tests could offer important new opportunities for t

114 ght to determine if urine lipoarabinomannan (LAM) would improve diagnosis of pulmonary TB.

115 cs, urine Xpert and urine-lipoarabinomannan (LAM) combined identified 88% of TB blood-culture-positiv

116 dmission (including urine lipoarabinomannan [LAM] detection) thought to be associated with 2-month mo

117 erculosis (positive urine lipoarabinomannan [LAM], urine Xpert MTB/RIF, or tuberculosis blood culture

118 of lipomannans (LM) and lipoarabinomannans (LAM) that are abundant components of the multilaminate c

119 Urinary liporabinomannan (LAM) testing has been previously restricted to HIV co-in

120 ene resulted in a complete loss of mature LM/LAM and the appearance of a truncated LM (t-LM).

121 ant with the NCgl2760 gene fully restored LM/LAM synthesis.

122 Lymphangioleiomyomatosis (LAM) is a fatal lung disease associated with germline or

123 Lymphangioleiomyomatosis (LAM) is a progressive destructive neoplasm of the lung a

124 Lymphangioleiomyomatosis (LAM) is a rare and progressive systemic disease affectin

125 Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that primarily affect

126 Lymphangioleiomyomatosis (LAM) is a rare disease in which LAM cells and fibroblast

127 Lymphangioleiomyomatosis (LAM) is a rare fatal cystic lung disease due to bi-allel

128 Lymphangioleiomyomatosis (LAM) is a rare, low-grade, metastasizing neoplasm that a

129 Complex (TSC) and Lymphangioleiomyomatosis (LAM) are caused by inactivating mutations in TSC1 or TSC

130 characteristics of lymphangioleiomyomatosis (LAM) and angiomyolipoma cells.

131 gical treatment of lymphangioleiomyomatosis (LAM) were recently published.

132 omas and pulmonary lymphangioleiomyomatosis (LAM).

133 Rationale: Lymphangioleiomyomatosis (LAM) is a metastatic neoplasm of reproductive-age women

134 closely related to lymphangioleiomyomatosis (LAM).

135 ic target for TSC, lymphangioleiomyomatosis (LAM), and other mTORC1-hyperactive tumors.

136 served Trem2(+) lipid-associated macrophage (LAM) subset and identify markers, spatial localization,

137 r (P-FAB) strategy for mannosylated LAM (Man-LAM or Mtb LAM) detection down to attomolar concentratio

138 biosensor (P-FAB) strategy for mannosylated LAM (Man-LAM or Mtb LAM) detection down to attomolar con

139 model-free method called Loss Angle Mapping (LAM).

140 O World Heritage site of L'Anse aux Meadows (LAM) in northern Newfoundland is the only undisputed sit

141 a lower limit of quantification of 15 pg/mL LAM, corresponding to 121 colony-forming units (CFUs)/mL

142 e globally inhibits the downstream molecular LAM program, leading to adipocyte hypertrophy as well as

143 not sufficient for the development of mouse LAM-like phenotype.

144 -Mtb LAM immunoglobulin M (IgM) and anti-Mtb LAM IgG respectively.

145 Moreover, the anti-Mtb LAM IgM bound sensor probes and the AuNP reagent stored

146 c (AuNP) labels functionalized with anti-Mtb LAM immunoglobulin M (IgM) and anti-Mtb LAM IgG respecti

147 P-FAB based Mtb LAM sensor demonstrates its potential for an on-site TB

148 rast to Pam(3)CSK(4) and FSL-1, we found Mtb LAM did not induce any of the classical PMN priming phen

149 Interestingly, Mtb LAM did not abrogate priming responses elicited by Pam(3

150 Moreover, Mtb LAM did not elicit p38 MAPK phosphorylation or endocytos

151 SK(4) We speculate that the inability of Mtb LAM to prime PMN may be due to differential localization

152 trategy for mannosylated LAM (Man-LAM or Mtb LAM) detection down to attomolar concentrations.

153 In summary, Mtb LAM activates PMN via TLR2/1, resulting in the productio

154 The Mtb LAM is quantified in terms of absorption of light passin

155 However, exposure of PMN to Mtb LAM did elicit pro- and anti-inflammatory cytokine produ

156 lipoarabinomannan from M. tuberculosis (Mtb LAM) would prime human PMN in a TLR2-dependent manner an

157 light membranes from Pam(3)CSK(4) versus Mtb LAM-stimulated cells demonstrated differential patterns

158 technology continues to improve, with newer LAM tests, such as Fujifilm SILVAMP TB LAM ('SILVAMP-LAM

159 ns in the tsc2 and tsc1 genes in the case of LAM.

160 ed tomography of the chest characteristic of LAM, but who have no additional confirmatory features of

161 The sources and cellular characteristics of LAM cells underlying disease pathogenesis remain elusive

162 ives: Identification and characterization of LAM cells in human lung and uterus using a single-cell a

163 The combination of LAM and AFB was significantly better than AFB alone amon

164 vel immunoassay to measure concentrations of LAM in sputum as a biomarker of bacterial load prior to

165 LAM-test and thus, improved the detection of LAM by the LAM-test in urine and milk that otherwise cou

166 ecific questions related to the diagnosis of LAM and management of pneumothoraces in patients with LA

167 tions against making a clinical diagnosis of LAM on the basis of the high-resolution computed tomogra

168 Effects of LAM on resident pulmonary cell types indicated recruitme

169 have no additional confirmatory features of LAM (i.e., clinical, radiologic, or serologic), the guid

170 d access to seven arabinomannan fragments of LAM (1-7).

171 of TB transmission to project the impact of LAM tests, distinguishing 'current' tests (with sensitiv

172 e, we generated a robust human cell model of LAM by reprogramming TSC2 mutation-bearing fibroblasts f

173 ped thus represent a novel cellular model of LAM that can advance our understanding of disease pathog

174 The origin of LAM cells is still unknown.

175 tic targets to influence the pathogenesis of LAM.

176 l mechanistic basis for the pathogenicity of LAM cells and they rationalize Src kinase as a novel the

177 els that accurately reflect the pathology of LAM have been challenging to develop.

178 al cells.Conclusions: A unique population of LAM(CORE) cells was identified in lung and uterus of pat

179 nic CD4(+) T cells primed in the presence of LAM also exhibited decreased response upon restimulation

180 The presence of LAM during primary stimulation of P25 TCR-transgenic mur

181 anergic state persisted after the removal of LAM.

182 Sensitivity of LAM increased significantly among participants with a lo

183 pletes the picture of how the active site of LAM from Clostridium subterminale SB4 "tames" the 5'-dAd

184 e enzymatic treatment at room temperature of LAM-spiked urine with alpha-mannosidase (for human TB),

185 lization strategy for producing a toolbox of LAM-OH derivatives under mild conditions.

186 a novel therapeutic target for treatment of LAM and TSC.

187 endations for the diagnosis and treatment of LAM.

188 The incremental yield of LAM increased with decreasing CD4 count.

189 sed as a reference, the incremental yield of LAM over Xpert was 29.6% (45/152) and that of Xpert over

190 st that cathepsin K activity is dependent on LAM cell-fibroblast interactions, and inhibitors of extr

191 gle-cell and single-nuclei RNA sequencing on LAM (n = 4) and control (n = 7) lungs, immunofluorescenc

192 1%) tested positive with Xpert (90, 9.3%) or LAM (34, 3.5%) assays.

193 rt was 29.6% (45/152) and that of Xpert over LAM was 75% (84/11).

194 We performed LAM LFA (on unprepared and supernatant CSF after heating

195 Urinary and PF LAM assays have low sensitivity but high specificity for

196 For PF LAM strip tests, switching cut-points from grade 1 to 2

197 roved it by 13.5%, and dual Xpert tests plus LAM testing improved it by 32.4%.

198 Patients with positive LAM or Xpert MTB/RIF results were referred for tuberculo

199 transplantation in patients with preexisting LAM resistance HBV.

200 and functional characteristics of pulmonary LAM cells.

201 ssay (LAM-ELISA) was developed to quantitate LAM concentration.

202 ith preexisting lamivudine (LAM) resistance (LAM-R) undergoing liver transplantation.

203 hepatitis B patients with preexisting rt204 LAM-R mutations or virological load refractory to LAM un

204 ughput genome-wide translocation sequencing (LAM-HTGTS) to map hundreds of thousands of RAG-initiated

205 ated high-throughput genome-wide sequencing (LAM-HTGTS) method for the detection of genome-wide 'prey

206 n was 70.7% (95% CI 59.0%-80.8%) for SILVAMP-LAM compared to 34.9% (95% CI 19.5%-50.9%) for LF-LAM.

207 s, such as Fujifilm SILVAMP TB LAM ('SILVAMP-LAM') showing improved sensitivity, including amongst HI

208 flow assay, Fujifilm SILVAMP TB LAM (SILVAMP-LAM), detects the presence of TB lipoarabinomannan (LAM)

209 hose with CD4 count > 200 cells/mul, SILVAMP-LAM sensitivity was 43.9% (95% CI 34.3%-53.9%), compared

210 ts with CD4 count 101-200 cells/mul, SILVAMP-LAM sensitivity was 62.7% (95% CI 52.4%-71.9%), compared

211 nts with CD4 count <= 100 cells/mul, SILVAMP-LAM sensitivity was 87.1% (95% CI 79.3%-93.6%), compared

212 alysis of the diagnostic accuracy of SILVAMP-LAM in adult PLHIV, including both published and unpubli

213 ference standard, the specificity of SILVAMP-LAM was 90.9% (95% CI 87.2%-93.7%), and that of LF-LAM 9

214 The sensitivity of SILVAMP-LAM was highest in patients with CD4 count <= 100 cells/

215 as well as clinically diagnosed TB), SILVAMP-LAM sensitivity was 65.8% (95% CI 55.9%-74.6%), and that

216 In this study, we found that SILVAMP-LAM identified a substantially higher proportion of TB p

217 , using blinded double reading, with SILVAMP-LAM and LF-LAM.

218 (having sensitivity consistent with SILVAMP-LAM).

219 supernatant CSF after heating and spinning), LAM ELISA, and Xpert MTB/RIF on the CSF samples.

220 mine LAM concentration in sputum, and sputum LAM measured by the assay may be used as a biomarker of

221 Declines in sputum LAM concentrations correlated with increases of MGIT TTD

222 There was a 1.29 log10 decrease of sputum LAM concentration, corresponding to an increase of 221 h

223 no examination of the correlation of sputum LAM to clinical cure.

224 ng independent cohorts from 2 other studies (LAM-RCT and a Medecins Sans Frontieres [MSF] cohort) fro

225 and, like other members of this superfamily, LAM utilizes radical-generating machinery comprising SAM

226 Symptomatic LAM occurs almost exclusively in females after menarche,

227 e Longitudinal Assessment of Manic Symptoms (LAM) study.

228 inary lipoarabinomannan (LAM) test (Alere TB LAM) and GeneXpert-MTB/RIF (Xpert) are useful for the di

229 rently licensed LAM test, Alere Determine TB LAM Ag ('LF-LAM'), performs best in the sickest people l

230 losis point-of-care test (Alere Determine TB LAM Ag [AlereLAM]) has suboptimal sensitivity, which res

231 , and having a positive urinary Determine TB LAM Ag test (Alere).

232 ipoarabinomannan (LAM) by Alere Determine TB LAM assay.

233 han an earlier LAM assay (Alere Determine TB LAM lateral flow assay [LF-LAM]).

234 ial lipoarabinomannan in urine (Determine TB LAM), and a molecular assay performed on a sputum sample

235 newer LAM tests, such as Fujifilm SILVAMP TB LAM ('SILVAMP-LAM') showing improved sensitivity, includ

236 The novel Fujifilm SILVAMP TB LAM (FujiLAM) assay has been developed to improve the se

237 sting, the point-of-care Fujifilm SILVAMP TB LAM (FujiLAM) could have rapidly diagnosed tuberculosis

238 apid lateral flow assay, Fujifilm SILVAMP TB LAM (SILVAMP-LAM), detects the presence of TB lipoarabin

239 erformed urine LAM testing (Determine(TM) TB LAM, Alere).

240 bbott, Waltham, MA, USA [formerly Alere]; TB-LAM) and concentrated urine Xpert (intervention).

241 firmed TB (Xpert MTB/RIF and/or Determine TB-LAM Ag positive) identified through screening HIV-positi

242 confirmed (Xpert MTB/RIF and/or Determine TB-LAM Ag positive) TB patients identified through screenin

243 sis lipoarabinomannan in urine (Determine TB-LAM Ag test, Abbott, Waltham, MA, USA [formerly Alere];

244 We retrospectively reviewed the Determine TB-LAM lateral flow assay (LF-LAM) results among human immu

245 Addition of TB-LAM and a single culture to Xpert confirmatory testing c

246 Addition of TB-LAM did not significantly increase diagnostic yield rela

247 A modified intervention of adding only TB-LAM to the standard of care was also evaluated.

248 er haemoglobin, and positive urine tests (TB-LAM and/or Xpert MTB/RIF) were associated with increased

249 wer hemoglobin, and positive urine tests (TB-LAM and/or Xpert MTB/RIF) were associated with increased

250 Addition of a single culture to TB-LAM and Xpert substantially improved ICF yield, identify

251 ening and confirmatory testing with urine TB-LAM (if CD4 count <=100 cells/mul), sputum Xpert, and/or

252 Urine TB-LAM is especially attractive because of high incremental

253 and Main Results: A unique cell type termed LAM(CORE) was identified, which was distinct from, but c

254 c Alere Determine Lipoarabinomannan Ag-test (LAM-test) detects Mycobacterium tuberculosis complex LAM

255 These results demonstrate that LAM upregulates GRAIL to induce anergy in Ag-reactive CD

256 We report here that LAM lesions and angiomyolipomas overexpress urokinase-ty

257 orm lung nodules and it is hypothesized that LAM nodule-derived proteases cause cyst formation and ti

258 These results suggest that LAM tests could have an important effect in averting TB

259 The LAM-ELISA detected all smear- and MTB-culture-positive s

260 The LAM-ELISA had a lower limit of quantification of 15 pg/m

261 d thus, improved the detection of LAM by the LAM-test in urine and milk that otherwise could be misse

262 fies a mesenchymal cell hub coordinating the LAM disease phenotype.

263 d randomized controlled trial evaluating the LAM test in hospitalized HIV-infected patients with susp

264 upporting a potential uterine origin for the LAM(CORE) cell.

265 Intriguingly, the LAM-like features of these cells suggest that haploinsuf

266 ed in LAM-associated fibroblasts but not the LAM cell line 621-101.

267 enhanced 10-fold the detection levels of the LAM-test and thus, improved the detection of LAM by the

268 suspected cattle to test the accuracy of the LAM-test when compared to results of positive TB detecti

269 Hence, we cannot recommend the LAM-test as a valid BTB diagnostic test in cattle using

270 These results indicate that the LAM-ELISA can determine LAM concentration in sputum, and

271 fer all features that define cancer upon the LAM cell-metabolic reprogramming and proliferative signa

272 sufficiency at the TSC2 locus contributes to LAM pathology, and demonstrated that iPSC reprogramming

273 mutations or virological load refractory to LAM undergoing liver transplantation were included, with

274 identify cell subtypes that are specific to LAM.

275 itional alveolar epithelial states unique to LAM lung.

276 -culture-positive samples, log10-transformed LAM concentration and MGIT time to detection (TTD) showe

277 uberous sclerosis complex (TSC) and LAM (TSC-LAM) into induced pluripotent stem cells (iPSC), followe

278 ghlighting the need for better understanding LAM's molecular etiology.

279 In this study we evaluate urinary LAM in HIV negative, pediatric and adult, pulmonary and

280 (3) from 3.5% to 50% (p < 0.001) for urinary LAM ELISA; for urinary LAM strip test, grade 1 and 2 cut

281 < 0.001) for urinary LAM ELISA; for urinary LAM strip test, grade 1 and 2 cut-points performed simil

282 The sensitivity of urinary LAM is increased in HIV-infected patients with a CD4 </=

283 Urine LAM testing may be most beneficial among patients with f

284 IF, 52.9%/94.2%; CSF LAM, 21.9%/94.2%; urine LAM, 24.1%/76.1%; and CSF glucose <40 mg/dl, and total p

285 MTB/RIF, CSF lipoarabinomannan (LAM), urine LAM, CSF total protein, and CSF glucose compared with th

286 Diagnostic sensitivities of urine LAM and sputum AFB were 42.1% (95% CI 29.1-55.9%) and 21

287 d mycobacterial culture, and performed urine LAM testing (Determine(TM) TB LAM, Alere).

288 The agreement between the urine LAM-test and USDA standard tests were poor at varying te

289 rfect accuracy, the need for access to urine LAM testing, modest study size, and not measuring all po

290 er of positive tests from urine Xpert, urine LAM and MTB-blood-culture correlated with PCs (p < 0.001

291 Urine Xpert, urine LAM and TB-blood-culture positive patients clustered sim

292 ned directly from isolated genomic DNA using LAM-PCR and unidirectionally ligated to bridge adapters;

293 roteomics were used to identify and validate LAM(CORE) cells and secreted biomarkers, predict cellula

294 ential Xpert followed by LAM and vice versa [LAM in Xpert-negative patients and Xpert in LAM-negative

295 omyomatosis (LAM) is a rare disease in which LAM cells and fibroblasts form lung nodules and it is hy

296 Africa, we examined the impact that widening LAM test eligibility would have on TB incidence and mort

297 noreactivity predominantly co-localized with LAM-associated fibroblasts.

298 the diagnosis and treatment of patients with LAM are provided.

299 entified in lung and uterus of patients with LAM, sharing close transcriptomic identity.

300 anagement of pneumothoraces in patients with LAM.